Upload
debi-sumarli
View
219
Download
0
Embed Size (px)
Citation preview
7/27/2019 Cervical Cancer Differential Diagnoses
1/8
22/08/13 Cervical Cancer Differential Diagnoses
emedicine.medscape.com/article/253513-differential 1/8
Cervical Cancer Differential Diagnoses
Author: Cecelia H Boardman, MD; Chief Editor: Warner K Huh, MD more...
Updated: Jul 1, 2013
Diagnostic Considerations
In addition to the conditions listed in the differential diagnosis, other disorders to consider in a woman with
possible cervical cancer include the following:
Cervicitis/infection, particularly granulomatous (which is rare)
Primary melanoma and Paget disease
Vaginal cancer
Another rare possibility is that a primary cancer elsewhere in the body has metastasized to the cervix.
Differential Diagnoses
Cervicitis
Endometrial Carcinoma
Pelvic Inflammatory Disease
Vaginitis
Medscape Reference
Reference
News
Reference
EducationMEDLINE
Contributor Information and DisclosuresAuthor
Cecelia H Boardman, MD The Dianne Harris Wright Professorship for Obstetrics and Gynecology Oncology
Research, Virginia Commonwealth University Medical Center; Associate Professor (Collateral), Department of
Obstetrics and Gynecology, Division of Gynecologic Oncology, Virginia Commonwealth University School of
Medicine
Cecelia H Boardman, MD is a member of the following medical societies: American College of Obstetric ians
and Gynecologists,American College of Surgeons, Minnesota Medical Association, and Society of
Gynecologist Oncologists
Disclosure: Merck Salary Speaking and teaching; Glaxo Salary Speaking and teaching; Depuy Salary
Speaking and teaching
Coauthor(s)
Kirk J Matthews Jr, MD Resident Physician, Department of Obstetrics and Gynecology, Virginia
http://www.sgo.org/http://www.acog.org/http://www.sgo.org/http://www.mmaonline.net/http://www.facs.org/http://www.acog.org/http://reference.medscape.com/http://emedicine.medscape.com/article/257141-overviewhttp://emedicine.medscape.com/article/256448-overviewhttp://emedicine.medscape.com/article/254083-overviewhttp://emedicine.medscape.com/article/253402-overview7/27/2019 Cervical Cancer Differential Diagnoses
2/8
22/08/13 Cervical Cancer Differential Diagnoses
emedicine.medscape.com/article/253513-differential 2/8
Commonwealth University Medical Center
Disclosure: Nothing to disclose.
Chief Editor
Warner K Huh, MD Professor, Department of Obstetrics and Gynecology, Division of Gynecologic Oncology,
Senior Scientist, Comprehensive Cancer Center, University of Alabama School of Medicine
Warner K Huh, MD is a member of the following medical societies:American College of Obstetricians and
Gynecologists,American College of Surgeons,American Society of Clinical Oncology, Massachusetts MedicalSociety, and Society of Gynecologist Oncologists
Disclosure: MERCK Consulting fee Consulting; ROCHE PHARMA/DIAGNOSTICS Consulting fee Consulting;
INTUITIVE SURGICAL Proctor Fee Consulting; Qiagen Consulting fee Consulting
Additional Contributors
A David Barnes, MD, PhD, MPH, FACOG Consulting Staff, Department of Obstetrics and Gynecology,
Mammoth Hospital (Mammoth Lakes, California), Pioneer Valley Hospital (Salt Lake City, Utah), Warren
General Hospital (Warren, Pennsylvania), and Mountain West Hospital (Tooele, Utah)
A David Barnes, MD, PhD, MPH, FACOG is a member of the following medical societies:American College of
Forensic Examiners,American College of Obstetricians and Gynecologists,American Medical Association,Association of Military Surgeons of the US, and Utah Medical Association
Disclosure: Nothing to disclose.
Anthony El-Khoueiry, MD Assistant Professor of Medicine, Clinical Instructor, Division of Medical Oncology,
Keck School of Medicine, University of Southern California
Disclosure: Nothing to disclose.
Agustin A Garcia, MD Associate Professor of Medicine, Keck School of Medicine, University of Southern
California
Disclosure: Nothing to disclose.
Omid Hamid, MD Associate Director of Melanoma Center, Medical Director of Neuro-oncology Clinic,
USC/Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California
Disclosure: Nothing to disclose.
John J Kavanagh JrMD, Chief, Professor, Department of Internal Medicine, Section of Gynecological and
Medical Therapeutics, MD Anderson Cancer Center, University of Texas Medical School at Houston
John J Kavanagh Jr is a member of the following medical societies: American Association for Cancer Research,
American Association for the Advancement of Science,American Association for the History of Medicine,
American College of Physicians,American Federation for Medical Research,American Medical Association,
Society of Gynecologist Oncologists, Southern Medical Association, and Texas Medical Association
Disclosure: Nothing to disclose.
Francisco Talavera, PharmD, PhD Adjunct Assistant Professor, University of Nebraska Medical Center
College of Pharmacy; Editor-in-Chief, Medscape Drug Reference
Disclosure: Medscape Salary Employment
References
1. Chustecka Z. Bevacizumab Prolongs Survival in Advanced Cervical Cancer. Medscape [serial online].
Available at http://www.medscape.com/viewarticle/805172. Accessed June 24, 2013.
2. Tewari KS, Sill M, Long HJ, et al. Incorporation of bevacizumab in the treatment of recurrent and
metastatic cervical cancer: A phase III randomized trial of the Gynecologic Oncology Group. Asco
University. Available at http://meetinglibrary.asco.org/content/116712-132. Accessed June 24, 2013.
http://meetinglibrary.asco.org/content/116712-132http://www.medscape.com/viewarticle/805172http://www.texmed.org/http://www.sma.org/http://www.sgo.org/http://www.ama-assn.org/http://www.afmr.org/http://www.acponline.org/http://www.histmed.org/http://www.aaas.org/http://www.aacr.org/http://www.utahmed.org/http://www.amsus.org/http://www.ama-assn.org/http://www.acog.org/http://www.acfei.com/http://www.sgo.org/http://www.massmed.org/AM/Template.cfm?Section=Homehttp://www.asco.org/http://www.facs.org/http://www.acog.org/7/27/2019 Cervical Cancer Differential Diagnoses
3/8
22/08/13 Cervical Cancer Differential Diagnoses
emedicine.medscape.com/article/253513-differential 3/8
3. Broder J. Pap tests less frequent under new guidelines. Medscape Medical News [serial online]. October
25, 2012;Accessed November 15, 2012. Available at http://www.medscape.com/viewarticle/773282.
4. American College of Obstetric ians and Gynecologists. Screening for cervical cancer. Obstet Gynecol.
Nov 2012;120(5):1222-38. [Medline].
5. [Guideline] Saslow D, Solomon D, Lawson HW, Killackey M, Kulasingam SL, Cain J, et al. American
Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for
Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. CA
Cancer J Clin. May 2012;62(3):147-72. [Medline].
6. U.S. Preventive Services Task Force. Screening for Cervical Cancer. AHRQ: Agency for Healthcare
Research and Quality. Available at http://www.uspreventiveservicestaskforce.org/uspstf/uspscerv.htm.
Accessed April 10, 2012.
7. Muoz N, Kjaer SK, Sigurdsson K, Iversen OE, Hernandez-Avila M, Wheeler CM, et al. Impact of human
papillomavirus (HPV)-6/11/16/18 vaccine on all HPV-associated genital diseases in young women. J Natl
Cancer Inst. Mar 3 2010;102(5):325-39. [Medline].
8. Gardasil. U.S. Food and Drug Administration. Available at
http://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM094042. Accessed
February 28, 2012.
9. FDA licensure of bivalent human papillomavirus vaccine (HPV2, Cervarix) for use in females and updated
HPV vaccination recommendations from the Advisory Committee on Immunization Practices (ACIP).
MMWR Morb Mortal Wk ly Rep. May 28 2010;59(20):626-9. [Medline].
10. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Cervical
Cancer Version 1 2012. Available at http://www.nccn.org/professionals/physician_gls/PDF/cervical.pdf.
Accessed April 16, 2012.
11. American Society for Colposcopy and Cervical Pathology. 2006 Consensus Guidelines. Available at
http://www.asccp.org/ConsensusGuidelines/tabid/7436/Default.aspx. Accessed August 18, 2011.
12. National Cancer Institute. Oral Contraceptives and Cancer Risk. Available athttp://www.cancer.gov/cancertopics/factsheet/Risk/oralcontraceptives. Accessed April 16, 2012.
13. Magnusson PK, Sparn P, Gyllensten UB. Genetic link to cervical tumours. Nature. Jul 1
1999;400(6739):29-30. [Medline].
14. Galloway DA. Papillomavirus vaccines in clinical trials. Lancet Infect Dis. Aug 2003;3(8):469-75.
[Medline].
15. Ghaderi M, Nikitina L, Peacock CS, Hjelmstrm P, Hallmans G, Wiklund F, et al. Tumor necrosis factor
a-11 and DR15-DQ6 (B*0602) haplotype increase the risk for cervical intraepithelial neoplasia in human
papillomavirus 16 seropositive women in Northern Sweden. Cancer Epidemiol Biomarkers Prev. Oct
2000;9(10):1067-70. [Medline].
16. Stanczuk GA, Sibanda EN, Tswana SA, Bergstrom S. Polymorphism at the -308-promoter position of the
tumor necrosis factor-alpha (TNF-alpha) gene and cervical cancer. Int J Gynecol Cancer. Mar-Apr
2003;13(2):148-53. [Medline].
17. Govan VA, Constant D, Hoffman M, Williamson AL. The allelic distribution of -308 Tumor Necrosis Factor-
alpha gene polymorphism in South African women with cervical cancer and control women. BMC Cancer.
Jan 26 2006;6:24. [Medline]. [Full Text].
18. Abrahamsson J, Carlsson B, Mellander L. Tumor necrosis factor-alpha in malignant disease. Am J
Pediatr Hematol Oncol. Nov 1993;15(4):364-9. [Medline].
19. Yang YC, Chang CL, Chen ML. Effect of p53 polymorphism on the susceptibility of cervical cancer.Gynecol Obstet Invest. 2001;51(3):197-201. [Medline].
20. Storey A, Thomas M, Kalita A, Harwood C, Gardiol D, Mantovani F, et al. Role of a p53 polymorphism in
the development of human papillomavirus-associated cancer. Nature. May 21 1998;393(6682):229-34.
[Medline].
http://reference.medscape.com/medline/abstract/9607760http://reference.medscape.com/medline/abstract/11306909http://reference.medscape.com/medline/abstract/8214357http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1397852/http://reference.medscape.com/medline/abstract/16438713http://reference.medscape.com/medline/abstract/12657115http://reference.medscape.com/medline/abstract/11045789http://reference.medscape.com/medline/abstract/12901889http://reference.medscape.com/medline/abstract/10403244http://www.cancer.gov/cancertopics/factsheet/Risk/oralcontraceptiveshttp://www.asccp.org/ConsensusGuidelines/tabid/7436/Default.aspxhttp://www.nccn.org/professionals/physician_gls/PDF/cervical.pdfhttp://reference.medscape.com/medline/abstract/20508593http://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM094042http://reference.medscape.com/medline/abstract/20139221http://www.uspreventiveservicestaskforce.org/uspstf/uspscerv.htmhttp://reference.medscape.com/medline/abstract/22422631http://reference.medscape.com/medline/abstract/23090560http://www.medscape.com/viewarticle/7732827/27/2019 Cervical Cancer Differential Diagnoses
4/8
22/08/13 Cervical Cancer Differential Diagnoses
emedicine.medscape.com/article/253513-differential 4/8
21. Andersson S, Rylander E, Strand A, Slls trm J, Wilander E. The significance of p53 codon 72
polymorphism for the development of cervical adenocarcinomas. Br J Cancer. Oct 19 2001;85(8):1153-6.
[Medline]. [Full Text].
22. Kim JW, Lee CG, Park YG, Kim KS, Kim IK, Sohn YW, et al. Combined analysis of germline
polymorphisms of p53, GSTM1, GSTT1, CYP1A1, and CYP2E1: relation to the incidence rate of cervical
carcinoma. Cancer. May 1 2000;88(9):2082-91. [Medline].
23. Lee SA, Kim JW, Roh JW, Choi JY, Lee KM, Yoo KY, et al. Genetic polymorphisms of GSTM1, p21, p53
and HPV infection with cervical cancer in Korean women. Gynecol Oncol. Apr 2004;93(1):14-8. [Medline].
24. } Wank R, Meulen JT, Luande J, Eberhardt HC, Pawlita M. Cervical intraepithelial neoplasia, cervical
carcinoma, and risk for patients with HLA-DQB1*0602,*301,*0303 alleles. Lancet. 1993 May
8;341(8854):1215.
25. Engelmark M, Beskow A, Magnusson J, Erlich H, Gyllensten U. Affected sib-pair analysis of the
contribution of HLA class I and class II loci to development of cervical cancer. Hum Mol Genet. Sep 1
2004;13(17):1951-8. [Medline].
26. Sastre-Garau X, Cartier I, Jourdan-Da Silva N, De Crmoux P, Lepage V, Charron D. Regression of low-
grade cervical intraepithelial neoplasia in patients with HLA-DRB1*13 genotype. Obstet Gynecol. Oct
2004;104(4):751-5. [Medline].
27. Mahmud SM, Robinson K, Richardson H, Tellier PP, Ferenczy AS, Roger M, et al. HLA polymorphisms
and cervical human Papillomavirus infection in a cohort of Montreal University students. J Infect Dis. Jul 1
2007;196(1):82-90. [Medline].
28. Chatterjee K, Dandara C, Hoffman M, Williamson AL. CCR2-V64I polymorphism is associated with
increased risk of cervical cancer but not with HPV infection or pre-cancerous lesions in African women.
BMC Cancer. Jun 10 2010;10:278. [Medline]. [Full Text].
29. Coelho A, Matos A, Catarino R, Pinto D, Sousa H, Pereira D, et al. The influence of chemokine receptor
CCR2 genotypes in the route to cervical carcinogenesis. Gynecol Obstet Invest. 2007;64(4):208-12.
[Medline].
30. Lai HC, Sytwu HK, Sun CA, Yu MH, Yu CP, Liu HS, et al. Single nucleotide polymorphism at Fas
promoter is associated with cervical carcinogenesis. Int J Cancer. Jan 10 2003;103(2):221-5. [Medline].
31. Sun T, Gao Y, Tan W, Ma S, Shi Y, Yao J, et al. A six-nucleotide insertion-deletion polymorphism in the
CASP8 promoter is associated with susceptibility to multiple cancers. Nat Genet. May 2007;39(5):605-
13. [Medline].
32. Sova P, Feng Q, Geiss G, Wood T, Strauss R, Rudolf V, et al. Discovery of novel methylation biomarkers
in cervical carcinoma by global demethylation and microarray analysis. Cancer Epidemiol Biomarkers
Prev. Jan 2006;15(1):114-23. [Medline].
33. Feng Q, Balasubramanian A, Hawes SE, Toure P, Sow PS, Dem A, et al. Detection of hypermethylated
genes in women with and without cervical neoplasia. J Natl Cancer Inst. Feb 16 2005;97(4):273-82.
[Medline].
34. de Sanjose S, Quint WG, Alemany L, Geraets DT, Klaustermeier JE, Lloveras B, et al. Human
papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide
study. Lancet Oncol. Nov 2010;11(11):1048-56. [Medline].
35. Bouvard V, Baan R, Straif K, Grosse Y, Secretan B, El Ghissassi F, et al. A review of human
carcinogens--Part B: biological agents. Lancet Oncol. Apr 2009;10(4):321-2. [Medline].
36. HIV Infection and Cancer Risk. National Cancer Institute. Available at
http://www.cancer.gov/cancertopics/factsheet/Risk/hiv-infection. Accessed February 28, 2012.
37. [Guideline] ACOG Practice Bulletin. Clinical Management Guidelines for Obstetrician-Gynecologists.
Number 61, April 2005. Human papillomavirus. Obstet Gynecol. Apr 2005;105(4):905-18. [Medline].
38. Arends MJ, Wyllie AH, Bird CC. Papillomaviruses and human cancer. Hum Pathol. Jul 1990;21(7):686-98.
[Medline].
http://reference.medscape.com/medline/abstract/2163360http://reference.medscape.com/medline/abstract/15802436http://www.cancer.gov/cancertopics/factsheet/Risk/hiv-infectionhttp://reference.medscape.com/medline/abstract/19350698http://reference.medscape.com/medline/abstract/20952254http://reference.medscape.com/medline/abstract/15713962http://reference.medscape.com/medline/abstract/16434596http://reference.medscape.com/medline/abstract/17450141http://reference.medscape.com/medline/abstract/12455036http://reference.medscape.com/medline/abstract/17664883http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2893113/http://reference.medscape.com/medline/abstract/20537184http://reference.medscape.com/medline/abstract/17538887http://reference.medscape.com/medline/abstract/15458897http://reference.medscape.com/medline/abstract/15238505http://reference.medscape.com/medline/abstract/15047208http://reference.medscape.com/medline/abstract/10813720http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2375157/http://reference.medscape.com/medline/abstract/117108287/27/2019 Cervical Cancer Differential Diagnoses
5/8
22/08/13 Cervical Cancer Differential Diagnoses
emedicine.medscape.com/article/253513-differential 5/8
39. Schiffman MH, Bauer HM, Hoover RN, Glass AG, Cadell DM, Rush BB, et al. Epidemiologic evidence
showing that human papillomavirus infection causes most cervical intraepithelial neoplasia. J Natl Cancer
Inst. Jun 16 1993;85(12):958-64. [Medline].
40. Liebrich C, Brummer O, Von Wasielewski R, Wegener G, Meijer C, Iftner T, et al. Primary cervical cancer
truly negative for high-risk human papillomavirus is a rare but distinct entity that can affect virgins and
young adolescents. Eur J Gynaecol Oncol. 2009;30(1):45-8. [Medline].
41. Hoover RN, Hyer M, Pfeiffer RM, Adam E, Bond B, Cheville AL, et al. Adverse health outcomes in women
exposed in utero to diethylstilbestrol. N Engl J Med. Oct 6 2011;365(14):1304-14. [Medline].
42. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin.
Mar-Apr 2011;61(2):69-90. [Medline].
43. American Cancer Society. Cancer Facts & Figures 2012. Available at
http://www.cancer.org/Research/CancerFactsFigures/CancerFactsFigures/cancer-facts-figures-2012.
Accessed February 28, 2012.
44. Solomon D, Breen N, McNeel T. Cervical cancer screening rates in the United States and the potential
impact of implementation of screening guidelines. CA Cancer J Clin. Mar-Apr 2007;57(2):105-11.
[Medline].
45. World Health Organization. WHO/ICO Information Centre on Human Papilloma Virus (HPV) and CervicalCancer. Available at http://www.who.int/hpvcentre/statistics/en . Accessed February 28, 2012.
46. Forouzanfar MH, Foreman KJ, Delossantos AM, Lozano R, Lopez AD, Murray CJ, et al. Breast and
cervical cancer in 187 countries between 1980 and 2010: a systematic analysis. Lancet. Oct 22
2011;378(9801):1461-84. [Medline].
47. Henley SJ, King JB, German RR, Richardson LC, Plescia M. Surveillance of screening-detected cancers
(colon and rectum, breast, and cervix) - United States, 2004-2006. MMWR Surveill Summ. Nov 26
2010;59(9):1-25. [Medline].
48. Vinh-Hung V, Bourgain C, Vlastos G, Cserni G, De Ridder M, Storme G, et al. Prognostic value of
histopathology and trends in cervical cancer: a SEER population study. BMC Cancer. Aug 23 2007;7:164.[Medline]. [Full Text].
49. Vinokurova S, Wentzensen N, Kraus I, Klaes R, Driesch C, Melsheimer P, et al. Type-dependent
integration frequency of human papillomavirus genomes in cervical lesions. Cancer Res. Jan 1
2008;68(1):307-13. [Medline].
50. Porras C, Rodrguez AC, Hildesheim A, Herrero R, Gonzlez P, Wacholder S, et al. Human
papillomavirus types by age in cervical cancer precursors: predominance of human papillomavirus 16 in
young women. Cancer Epidemiol Biomarkers Prev. Mar 2009;18(3):863-5. [Medline]. [Full Text].
51. Surveillance Epidemiology and End Results. SEER Stat Fact Sheets: Cervix Uteri. National Cancer
Institute. Available at http://seer.cancer.gov/statfacts/html/cervix.html . Accessed April 16, 2012.
52. Everett T, Bryant A, Griffin MF, Martin-Hirsch PP, Forbes CA, Jepson RG. Interventions targeted at
women to encourage the uptake of cervical screening. Cochrane Database Syst Rev. May 11
2011;CD002834. [Medline].
53. Pecorelli S, Zigliani L, Odicino F. Revised FIGO staging for carcinoma of the cervix. Int J Gynaecol
Obstet. May 2009;105(2):107-8. [Medline].
54. Barclay L. Cervical Screening Guidelines Updated. Available at
http://www.medscape.com/viewarticle/781190. Accessed April 5, 2013.
55. Massad LS, Einstein MH, Huh WK, Katki HA, Kinney WK, Schiffman M, et al. 2012 updated consensus
guidelines for the management of abnormal cervical cancer screening tests and cancer precursors. J LowGenit Tract Dis. Apr 2013;17(5 Suppl 1):S1-S27. [Medline].
56. Siebers AG, Klinkhamer PJ, Vedder JE, Arbyn M, Bulten J. Causes and relevance of unsatisfactory and
satisfactory but limited smears of liquid-based compared with conventional cervical cytology. Arch Pathol
Lab Med. Jan 2012;136(1):76-83. [Medline].
http://reference.medscape.com/medline/abstract/22208490http://reference.medscape.com/medline/abstract/23519301http://www.medscape.com/viewarticle/781190http://reference.medscape.com/medline/abstract/19342051http://reference.medscape.com/medline/abstract/21563135http://seer.cancer.gov/statfacts/html/cervix.htmlhttp://www.ncbi.nlm.nih.gov/pmc/articles/PMC2772192/http://reference.medscape.com/medline/abstract/19273486http://reference.medscape.com/medline/abstract/18172324http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1994954/http://reference.medscape.com/medline/abstract/17718897http://reference.medscape.com/medline/abstract/21102407http://reference.medscape.com/medline/abstract/21924486http://www.who.int/hpvcentre/statistics/enhttp://reference.medscape.com/medline/abstract/17392387http://www.cancer.org/Research/CancerFactsFigures/CancerFactsFigures/cancer-facts-figures-2012http://reference.medscape.com/medline/abstract/21296855http://reference.medscape.com/medline/abstract/21991952http://reference.medscape.com/medline/abstract/19317256http://reference.medscape.com/medline/abstract/83884787/27/2019 Cervical Cancer Differential Diagnoses
6/8
22/08/13 Cervical Cancer Differential Diagnoses
emedicine.medscape.com/article/253513-differential 6/8
57. Chen YB, Hu CM, Chen GL, Hu D, Liao J. Staging of uterine cervical carcinoma: whole-body diffusion-
weighted magnetic resonance imaging.Abdom Imaging. Oct 2011;36(5):619-26. [Medline].
58. Solomon D, Davey D, Kurman R, Moriarty A, O'Connor D, Prey M, et al. The 2001 Bethesda System:
terminology for reporting results of cervical cytology. JAMA. Apr 24 2002;287(16):2114-9. [Medline].
59. American Joint Committee on Cancer. Cervix uteri. In:.AJCC Cancer Staging Manual. 6th ed. New York:
Springer; 2002:259-65..
60. Speiser D, Mangler M, Khler C, Hasenbein K, Hertel H, Chiantera V, et al. Fertility outcome after radical
vaginal trachelectomy: a prospective study of 212 patients. Int J Gynecol Cancer. Dec 2011;21(9):1635-9.
[Medline].
61. Beiner ME, Hauspy J, Rosen B, Murphy J, Laframboise S, Nofech-Mozes S, et al. Radical vaginal
trachelectomy vs. radical hysterectomy for small early stage cervical cancer: a matched case-control
study. Gynecol Oncol. Aug 2008;110(2):168-71. [Medline].
62. Lowe MP, Chamberlain DH, Kamelle SA, Johnson PR, Tillmanns TD. A multi-inst itutional experience with
robotic-assisted radical hysterectomy for early stage cervical cancer. Gynecol Oncol. May
2009;113(2):191-4. [Medline].
63. Nezhat FR, Datta MS, Liu C, Chuang L, Zakashansky K. Robotic radical hysterectomy versus total
laparoscopic radical hysterectomy with pelvic lymphadenectomy for treatment of early cervical cancer.JSLS. Jul-Sep 2008;12(3):227-37. [Medline]. [Full Text].
64. Cantrell LA, Mendivil A, Gehrig PA, Boggess JF. Survival outcomes for women undergoing type III robotic
radical hysterectomy for cervical cancer: a 3-year experience. Gynecol Oncol. May 2010;117(2):260-5.
[Medline].
65. Shah M, Lewin SN, Deutsch I, Burke WM, Sun X, Herzog TJ, et al. Therapeutic role of lymphadenectomy
for cervical cancer. Cancer. Jan 15 2011;117(2):310-7. [Medline].
66. Sedlis A, Bundy BN, Rotman MZ, Lentz SS, Muderspach LI, Zaino RJ. A randomized trial of pelvic
radiation therapy versus no further therapy in selected patients with stage IB carcinoma of the cervix after
radical hysterectomy and pelvic lymphadenectomy: A Gynecologic Oncology Group Study. GynecolOncol. May 1999;73(2):177-83. [Medline].
67. Peters WA 3rd, Liu PY, Barrett RJ 2nd, Stock RJ, Monk BJ, Berek JS, et al. Concurrent chemotherapy
and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical
surgery in high-risk early-stage cancer of the cervix. J Clin Oncol. Apr 2000;18(8):1606-13. [Medline].
68. Morris M, Eifel PJ, Lu J, Grigsby PW, Levenback C, Stevens RE, et al. Pelvic radiation with concurrent
chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer. N Engl J Med.
Apr 15 1999;340(15):1137-43. [Medline].
69. Rose PG, Bundy BN, Watk ins EB, Thigpen JT, Deppe G, Maiman MA, et al. Concurrent cisplatin-based
radiotherapy and chemotherapy for locally advanced cervical cancer. N Engl J Med. Apr 15
1999;340(15):1144-53. [Medline].
70. Keys HM, Bundy BN, Stehman FB, Muderspach LI, Chafe WE, Suggs CL 3rd, et al. Cisplatin, radiation,
and adjuvant hysterectomy compared with radiation and adjuvant hysterectomy for bulky stage IB cervical
carcinoma. N Engl J Med. Apr 15 1999;340(15):1154-61. [Medline].
71. ACOG practice bulletin. Diagnosis and treatment of cervical carcinomas. Number 35, May 2002.
American College of Obstetricians and Gynecologists. Int J Gynaecol Obstet. Jul 2002;78(1):79-91.
[Medline].
72. Long HJ 3rd, Bundy BN, Grendys EC Jr, Benda JA, McMeekin DS, Sorosky J, et al. Randomized phase
III trial of cisplatin with or without topotecan in carcinoma of the uterine cervix: a Gynecologic Oncology
Group Study. J Clin Oncol. Jul 20 2005;23(21):4626-33. [Medline].
73. [Best Evidence] Monk BJ, Sill MW, McMeekin DS, Cohn DE, Ramondetta LM, Boardman CH, et al.
Phase III trial of four cisplatin-containing doublet combinations in stage IVB, recurrent, or persistent
cervical carcinoma: a Gynecologic Oncology Group study. J Clin Oncol. Oct 1 2009;27(28):4649-55.
[Medline]. [Full Text].
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2754911/http://reference.medscape.com/medline/abstract/19720909http://reference.medscape.com/medline/abstract/15911865http://reference.medscape.com/medline/abstract/12197489http://reference.medscape.com/medline/abstract/10202166http://reference.medscape.com/medline/abstract/10202165http://reference.medscape.com/medline/abstract/10202164http://reference.medscape.com/medline/abstract/10764420http://reference.medscape.com/medline/abstract/10329031http://reference.medscape.com/medline/abstract/20862747http://reference.medscape.com/medline/abstract/20153886http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3015864/http://reference.medscape.com/medline/abstract/18765043http://reference.medscape.com/medline/abstract/19249082http://reference.medscape.com/medline/abstract/18539313http://reference.medscape.com/medline/abstract/21795986http://reference.medscape.com/medline/abstract/11966386http://reference.medscape.com/medline/abstract/207304237/27/2019 Cervical Cancer Differential Diagnoses
7/8
22/08/13 Cervical Cancer Differential Diagnoses
emedicine.medscape.com/article/253513-differential 7/8
Medscape Reference 2011 WebMD, LLC
74. Berek JS, Howe C, Lagasse LD, Hacker NF. Pelvic exenteration for recurrent gynecologic malignancy:
survival and morbidity analysis of the 45-year experience at UCLA. Gynecol Oncol. Oct 2005;99(1):153-9.
[Medline].
75. Goldberg GL, Sukumvanich P, Einstein MH, Smith HO, Anderson PS, Fields AL. Total pelvic
exenteration: the Albert Einstein College of Medicine/Montefiore Medical Center Experience (1987 to
2003). Gynecol Oncol. May 2006;101(2):261-8. [Medline].
76. Moore DH. Chemotherapy for advanced, recurrent, and metastatic cervical cancer. J Natl Compr Canc
Netw. Jan 2008;6(1):53-7. [Medline].
77. Moore DH, Blessing JA, McQuellon RP, Thaler HT, Cella D, Benda J, et al. Phase III study of cisplatin
with or without paclitaxel in stage IVB, recurrent, or persistent squamous cell carcinoma of the cervix: a
gynecologic oncology group study. J Clin Oncol. Aug 1 2004;22(15):3113-9. [Medline].
78. Moore KN, Herzog TJ, Lewin S, Giuntoli RL, Armstrong DK, Rocconi RP, et al. A comparison of
cisplatin/paclitaxel and carboplatin/paclitaxel in stage IVB, recurrent or persistent cervical cancer.
Gynecol Oncol. May 2007;105(2):299-303. [Medline].
79. Mulcahy N. Bevacizumab extends survival in advanced cervical cancer. Medscape Medical News.
Available at http://www.medscape.com/viewarticle/779002. Accessed February 13, 2013.
80. Winer RL, Lee SK, Hughes JP, Adam DE, Kiviat NB, Koutsky LA. Genital human papillomavirus infection:incidence and risk factors in a cohort of female university students. Am J Epidemiol. Feb 1
2003;157(3):218-26. [Medline].
81. Repp KK, Nielson CM, Fu R, Schafer S, Lazcano-Ponce E, Salmern J, et al. Male human papillomavirus
prevalence and association with condom use in Brazil, Mexico, and the United States. J Infect Dis. Apr
2012;205(8):1287-93. [Medline]. [Full Text].
82. Roberts JN, Buck CB, Thompson CD, Kines R, Bernardo M, Choyke PL, et al. Genital transmission of
HPV in a mouse model is potentiated by nonoxynol-9 and inhibited by carrageenan. Nat Med. Jul
2007;13(7):857-61. [Medline].
83. Lehtinen M, Paavonen J, Wheeler CM, Jaisamrarn U, Garland SM, Castellsagu X, et al. Overall efficacyof HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year
end-of-study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncol. Jan 2012;13(1):89-
99. [Medline].
84. Wheeler CM, Castellsagu X, Garland SM, Szarewski A, Paavonen J, Naud P, et al. Cross-protect ive
efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-
vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA
trial. Lancet Oncol. Jan 2012;13(1):100-10. [Medline].
85. Centers for Disease Control and Prevention. ACIP Recommendations. Available at
http://www.cdc.gov/vaccines/pubs/ACIP-list.htm#hpv. Accessed April 17, 2012.
86. Recommendations on the use of quadrivalent human papillomavirus vaccine in males--Advisory
Committee on Immunization Practices (ACIP), 2011. MMWR Morb Mortal Wkly Rep. Dec 23
2011;60(50):1705-8. [Medline].
87. Roteli-Martins C, Naud P, De Borba P, Teixeira J, De Carvalho N, Zahaf T, et al. Sustained
immunogenicity and efficacy of the HPV-16/18 AS04-adjuvanted vaccine: up to 8.4 years of follow-up.
Hum Vaccin Immunother. Mar 1 2012;8(3):[Medline].
88. Slade BA, Leidel L, Vellozzi C, Woo EJ, Hua W, Sutherland A, et al. Postlicensure safety surveillance for
quadrivalent human papillomavirus recombinant vaccine. JAMA. Aug 19 2009;302(7):750-7. [Medline].
89. Mulcahy N. Bevacizumab Extends Survival in Advanced Cervical Cancer. Available at
http://www.medscape.com/viewarticle/779002. Accessed February 20, 2013.
http://www.medscape.com/viewarticle/779002http://reference.medscape.com/medline/abstract/19690307http://reference.medscape.com/medline/abstract/22327492http://reference.medscape.com/medline/abstract/22189893http://www.cdc.gov/vaccines/pubs/ACIP-list.htm#hpvhttp://reference.medscape.com/medline/abstract/22075170http://reference.medscape.com/medline/abstract/22075171http://reference.medscape.com/medline/abstract/17603495http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3308908/http://reference.medscape.com/medline/abstract/22396601http://reference.medscape.com/medline/abstract/12543621http://www.medscape.com/viewarticle/779002http://reference.medscape.com/medline/abstract/17303230http://reference.medscape.com/medline/abstract/15284262http://reference.medscape.com/medline/abstract/18267059http://reference.medscape.com/medline/abstract/16426668http://reference.medscape.com/medline/abstract/160546787/27/2019 Cervical Cancer Differential Diagnoses
8/8
SearchSearch